Tamil Nadu government asserts that Coldrif cough syrup samples show dangerously high levels of diethylene glycol (DEG). Yet Madhya Pradesh authorities push back, saying some tested batches appear uncontaminated, fueling a clash over responsibility amid mounting child deaths.
Glimpse:
The Tamil Nadu Drugs Control Department has alleged toxicity in Coldrif syrup, claiming independent tests from its labs have detected diethylene glycol (DEG) well above safe thresholds. However, Madhya Pradesh regulators counter that several batches they examined showed no signs of contamination, provoking tension between state agencies. The dispute comes amid a backdrop of tragic child fatalities in central India reportedly linked to the syrup. Both states are racing to validate lab results, trace supply chains, and identify how the dangerous substance entered the product. As families demand answers, the controversy raises deeper questions of pharmaceutical oversight, state center coordination, and public trust in medicine safety.
The Coldrif saga has entered a new chapter and this time, it’s not just about bans and arrests. Tamil Nadu has now publicly alleged that the syrup is toxic, citing lab reports showing perilous concentrations of diethylene glycol (DEG), while Madhya Pradesh refutes full contamination, pointing to “clean” test results in multiple samples.
According to the Tamil Nadu Drugs Control wing, they independently gathered samples from the company’s facility and distribution chain and tested them. The results, the state claims, reveal DEG levels that far exceed permissible safety margins. The implication: the toxic ingredient was not a downstream adulteration but an internal lapse within manufacturing.
Meanwhile, Madhya Pradesh’s Food & Drug Administration isn’t fully on board with that narrative. Their tests, in several instances, reportedly returned normal results. Some officials in MP say the toxic batches might be isolated, or contamination may be linked to specific lots, rather than the entire production. They argue that Tamil Nadu’s claims risk broad panic and may unfairly implicate unaffected stock.
This tug of war over testing methodology, sample validity, and chain of custody adds confusion amid tragedy. Families who lost young children are left wondering: was the contamination systemic or patchy? Which samples can be trusted? Who is being held accountable?
Both states are now racing to:
- Cross validate samples sending them to third party, neutral labs for confirmatory testing.
- Trace distribution mapping which batches went where, to find geographic patterns.
- Inspect manufacturing protocols drilling into raw material sourcing, record logs, and safety controls inside the factory.
- Communicate clearly to the public issuing recall mandates, usage advisories, and stock freezes.
The public health stakes are enormous. Parents struggle to reconcile daily healthcare decisions is giving a child a cough syrup safe or lethal? Regulators must not only get to the truth but restore confidence in medicines and oversight.
“Our lab data show DEG levels in Coldrif far beyond safety norms this is not contamination by accident, it is a serious manufacturing failure,”
By
HB Team
